We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bayer Ord | BYR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 55.93 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 55.93 |
| Top Posts |
|---|
Posted at 09/9/2007 09:22 by ariane Bayer's Drug PipelineMay Have a Big Winner By GEORGE FREY September 9, 2007 The only time many American investors think of Bayer (BAY) is when they have a headache. But the German company could be worth considering by those who want to diversify their U.S. stock holdings. The pharmaceutical and chemical maker, whose American depositary shares trade on the New York Stock Exchange, just reported strong quarterly results. It has a promising product pipeline and good profit outlook. And it's even the subject of takeover rumors. While most analysts doubt there's substance to the takeover speculation, it's clear what Bayer's attractions would be: A restructuring and a slew of purchases and divestitures have left the concern more efficient and more focused on the bottom line. Bayer's second-quarter profit rose 46%, to 660 million euros ($904 million) from 452 million euros a year earlier. Sales jumped 22%, to 8.22 billion euros. The results were bolstered by inclusion of drug maker Schering, which Bayer bought in 2006. (Schering isn't related to the U.S.'s Schering-Plough.) Bayer Chief Executive Werner Wenning won't comment on the takeover rumors, which have Switzerland's Novartis as a possible suitor. (Novartis hasn't publicly commented, either). But he voices a bright outlook for Bayer's core health-care division. Bayer predicts that 2007 sales will rise more than 10% above 2006's 28.96 billion euros. And with some 20 drugs in Phase III testing, 17 in Phase II and 14 in Phase I, Bayer's future looks better than many rivals', says Andrew Benson, a Citigroup analyst in London. He calls the anti- coagulant drug Rivaroxaban, aimed at helping stroke victims, "the jewel in the crown." Munich-based UniCredit analyst Isabella Zinck says Rivaroxaban could go on the market at the end of 2008 in Europe, and in 2009 in the U.S. Johnson & Johnson, which is sharing in Rivaroxaban's development costs, will get rights for primary-care sales in the U.S. Bayer will get the rights to U.S. specialty-care sales and sales outside the U.S. Mr. Benson has a buy rating on Bayer with a target price of about $88 for its American depositary receipts, which traded recently at about $76. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
